Duvortuxizumab

Drug Profile

Duvortuxizumab

Alternative Names: Anti-CD3/CD19 monoclonal-antibody; CD3-CD19 DART protein; CD3xCD19 DART molecule; JNJ-64052781; MGD 011

Latest Information Update: 07 Oct 2016

Price : $50

At a glance

  • Originator MacroGenics
  • Developer Janssen Biotech; MacroGenics
  • Class Bispecific antibodies
  • Mechanism of Action CD19 antigen modulators; CD3 antigen modulators; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Haematological malignancies; Mantle-cell lymphoma

Most Recent Events

  • 07 Oct 2016 Janssen Research & Development suspends a phase I trial in Chronic lymphocytic leukaemia in USA, Australia and United Kingdom (NCT02743546)
  • 16 Sep 2016 JNJ 64052781 is now called duvortuxizumab (NCT02743546)
  • 01 Aug 2016 Phase-I clinical trials in Chronic lymphocytic leukaemia (Combination therapy, Second-line therapy or greater) in United Kingdom (IV) after August 2016 (NCT02743546)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top